5-year GLP-1 data raises red flags for bone and joint health. What next?

By the time GLP-1s hit the mainstream as weight-loss and diabetes therapies, most clinicians were already comfortable touting their cardiometabolic benefits: improved glycemic control, meaningful weight reduction, and, in some high-risk patients, fewer cardiovascular events.^[]

But new musculoskeletal findings have complicated that conversation. A large analysis presented earlier in 2026 suggested people with obesity and type 2 diabetes treated with GLP-1 receptor agonists were more likely to develop osteoporosis and gout over a 5-year period compared with matched controls.^[]

In this cohort, approximately 4% of GLP-1 users developed osteoporosis, compared with just over 3% of nonusers—roughly a 30% relative increase—while rates of gout were also slightly higher.

“People are taking these medications, and obviously there’s a tremendous amount of upside. But with that, they start to decrease their intake of food and nutrients,” John Horneff, MD, an associate professor of orthopedic surgery at the University of Pennsylvania, told NBC News.^[]

“Weight loss does cause bone loss,” Clifford Rosen, MD, a professor of medicine at Tufts University, told NBC News. “The question we’ve been studying is whether this is a normal compensation of the skeleton, it’s just reshaping itself, or whether this is truly a risk for losing bone that’s more rapid than what would be expected.”^[]

However, these data are observational; uncorrected for lifestyle factors, nutrient intake, or imaging changes in bone strength; and do not prove causality.

In short, the musculoskeletal footprint of GLP-1 therapy is heterogeneous and far from settled.

Semaglutide and osteoarthritis: A potentially game-changing signal

Against this backdrop of potential risk, exciting early research recently published in Cell Metabolism shows that semaglutide may reverse tissue damage associated with osteoarthritis through mechanisms independent of weight loss.^[]

In both preclinical mouse models and a small human pilot trial, semaglutide enhanced energy metabolism in chondrocytes by shifting them from glycolysis to oxidative phosphorylation. Treated joints had reduced cartilage degeneration, fewer osteophytes, reduced pain, and improved function, even when weight remained constant.

Whether these cartilage-protective effects translate broadly to patients who are not overweight, or apply to other joints, is unclear, and more research is needed.^[]

Interpreting conflicting signals

What we have now is a nuanced picture of what GLP-1 therapies mean for bone and joint health:

So, what should you tell patients?

Here’s a practical, clinically oriented framework for discussing these findings:

1. Acknowledge the benefits—but contextualize them

GLP-1 receptor agonists are powerful tools for obesity and diabetes management, with benefits that can extend to joint symptoms (particularly osteoarthritis pain and function).^[]

2. Assess baseline risk

Before initiating GLP-1 therapy in patients at high risk for bone loss (e.g., those who are postmenopausal, older, or who have prior fractures), consider:

• A baseline DXA scan and review of risk factors

• Optimizing calcium and vitamin D levels

• Assessing baseline uric acid and gout history

3. Set realistic expectations

Let patients know that while semaglutide may help joint symptoms, especially in osteoarthritis, this isn’t yet an FDA-approved indication—and larger confirmatory studies are underway.

4. Monitor during therapy

For patients on long-term GLP-1 therapy, especially those losing significant weight:

• Consider periodic bone density monitoring

• Be attentive to symptoms of musculoskeletal pain beyond expected post-weight loss effects

• Evaluate gout risk—rapid weight reduction and shifting urate metabolism may increase flares

5. Mitigate modifiable factors